⌘K
t
CRISM Therapeutics Corporation held its Annual General Meeting on 26 August 2025. All 13 resolutions put to shareholders were duly passed, with "Votes for %" ranging from 99.99% to 100.00% across the resolutions.
| Date | 26 Aug 2025 |
| Time | 16:03:57 |
| Category | AGMs and other meetings |
| ID | 7323W |
26 August 2025
CRISM Therapeutics Corporation
("CRISM", "CRISM Therapeutics" or the "Company")
Result of AGM
CRISM Therapeutics (AIM: CRTX), the innovative UK drug delivery company focused on the localised delivery of chemotherapy drugs, is pleased to confirm that at the Company's Annual General Meeting held earlier today, all resolutions were duly passed. Full details of the resolutions are set out in the Notice of Annual General Meeting dated 4 August 2025 and available on the Company's website at: https://www.crismtherapeutics.com/documents-and-notices
The votes cast were as follows:
|
Resolution |
Votes for |
Votes for % |
Votes against |
Votes against % |
Abstentions |
|
1 |
5,094,571 |
100.00% |
- |
- |
62 |
|
2 |
5,094,049 |
99.99% |
510 |
0.01% |
74 |
|
3 |
5,094,571 |
100.00% |
- |
- |
62 |
|
4 |
5,094,571 |
100.00% |
- |
- |
62 |
|
5 |
5,094,571 |
100.00% |
- |
- |
62 |
|
6 |
5,094,559 |
100.00% |
- |
- |
74 |
|
7 |
5,094,571 |
100.00% |
- |
- |
62 |
|
8 |
5,094,049 |
99.99% |
572 |
0.01% |
12 |
|
9 |
5,094,049 |
99.99% |
572 |
0.01% |
12 |
|
10 |
5,094,049 |
99.99% |
572 |
0.01% |
12 |
|
11 |
5,094,213 |
99.99% |
346 |
0.01% |
74 |
|
12 |
5,094,213 |
99.99% |
408 |
0.01% |
12 |
|
13 |
5,094,213 |
99.99% |
408 |
0.01% |
12 |
-Ends-
Enquiries:
|
Company |
Nomad and Broker |
Financial PR |
|
CRISM Therapeutics Corporation |
S.P. Angel Corporate Finance LLP |
Burson Buchanan |
|
Andrew Webb, CEO Chris McConville, CSO |
Richard Morrison Vadim Alexandre Adam Cowl |
Mark Court / Jamie Hooper CRISM@buchanancomms.co.uk |
|
via Burson Buchanan |
+44 (0) 20 3470 0470 |
+44 (0) 20 7466 5000 |
About CRISM Therapeutics Corporation
CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.
ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.
For more information please visit: https://www.crismtherapeutics.com/
The Company's LEI is 213800XFW6MKVCHHPW88.